http://columbiabroadcast.spaces.live.com
ptusss@aol.com
United States Secret Service Director Patty Martinez President Pro Tempro
5 USCS section 5301 (c) "The President's Pay Agent" New in Caution to 'settlement of payment cards" ~ VOUCHERS ~ electronic 26 USCS section 6050W returns 12/31/2010; Travel and Subsistence Expenses; mileage allowance 5 USCS section 5701 without pay or $1.00 a year authorize employment. Confidentality Notice: This E-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the E-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this E-mail is strictly prohibited. If you have received this E-mail transmission in Error, please reply to the sender, so arrangements can be made for proper delivery, and then delete the message from your system. Please consider the environment before printing this email. Notice of Removal of office of Defendant Article IV General Provisions Section 2 (Supreme Law of The Land) The Constitution of The United States. "Any Thing in The Constitution or Laws of any State to the Contrary Notwithstanding" Contrary to Law (of an Act or Omission) Illegal; In Notwithstanding "Dispite;in spite of The government is current Executive Branch violating Notice of Removal, The Notice of Removal on the Obama Administration in personam including Goods (including tea, i.e. Leslie in like); within 30 days after the defendant Barak Obama is served with process in suit (case 641210) 28 USCS section 1446; Murphy Bros., Inc Vs. Michetti Pipe Stringing Inc., 119 S.Ct 1322 (1999). In responce to Housekeeper statment of Court Process of Subject Matter California Inn in Notice of Removal. Create a new office Federal Districts Modesto City Schools Districts and Turlock Irrigation District Division 3; United States Department of Education, Director Ross Carkeet United States Department of Education, Federal Bureau of Investigation Youth Authorty Director Guy Perea, Jr., Federal Bureau of Investigation Youth Authority Director Shopie Perea, and Director United States District Court Western Washington Clean Water United States Navy.
Date: Fri, 6 May 2011 14:27:19 -0500
From: fda@service.govdelivery.com
Subject: FDA MedWatch - Needleless Pre-filled Glass Syringes: Drug Safety Communication - Compatibility Problems with Needleless Intravenous Access Systems
To: guyperea@live.com
  |
Needleless Pre-filled Glass Syringes: Drug Safety Communication - Compatibility Problems with Needleless Intravenous Access Systems
Reports Received on Adenosine and Amiodarone Products
[UPDATED 05/06/2011] FDA recommends that, to reduce the potential risks to patients, healthcare professionals and risk managers stock crash carts, ambulances, and emergency rooms with adenosine and amiodarone supplied in vials or pre-filled plastic syringes, if possible. The use of needleless pre-filled glass syringes in emergency situations should be avoided.Refer to the May 2011 FDA Drug Safety Communication, featuring photos, a list of affected adenosine and amiodarone products, and IV access systems known to be incompatible with adenosine and amiodarone pre-filled glass syringes.
[Posted 11/17/2010]
AUDIENCE: Critical Care Medicine, Emergency Medicine, Cardiology, Risk Manager
ISSUE: FDA is notifying healthcare professionals, especially those working in emergency and critical care settings, of reports of compatibility problems when certain needleless pre-filled glass syringes are used with some needleless intravenous (IV) access systems. These syringes may malfunction, break, or become clogged during the process of attempting to connect to needleless IV access systems. Most of the reports have been related to pre-filled needleless glass syringes that contain adenosine, often when attempting to connect to some pin activated needleless IV access systems. Adenosine is a cardiac drug that is administered when a patient has a rapid or irregular heart rhythm in an attempt to return their heart rhythm to normal. Adenosine must be injected rapidly into the blood stream in emergency situations and this failure could delay treatment.
In some cases where an attempt is made to connect to pin activated needleless IV access systems, the syringe may cause the pin to break thus clogging the syringe, or damaging the IV tubing and/or the needleless connector and requiring reestablishment of a new intravenous access. These failures can cause a delay in administration of the medication, which could potentially result in serious harm to patients.
BACKGROUND: Adenosine pre-filled glass syringes are marketed by Teva, Sagent, Baxter, and Wockhardt. FDA has also received reports of problems related to certain pre-filled needleless glass syringes containing the cardiac drug amiodarone. See the FDA letter for a list of affected adenosine and amiodarone products.
RECOMMENDATION: Healthcare professionals, risk managers, and staff who purchase, stock, or administer emergency crash cart medications, operating room medications, emergency drug boxes, or types of emergency drug caches should be alerted to this incompatibility problem and potential for damage or blockage of the IV line and delay in administering the medication. Healthcare organizations currently using glass prefilled syringes should consider stocking adenosine supplied in vials or pre-filled plastic syringes as a back up measure.
FDA has expanded the scope of its review to include all currently marketed pre-filled needleless glass syringes intended for use with needleless intravenous access systems, where delay in administration could potentially result in a life threatening event. FDA is working with manufacturers to correct the problem and identify additional mitigation strategies.
Healthcare professionals and healthcare organization managers are encouraged to report adverse events or problems experienced with the use of needleless pre-filled glass syringes to the FDA's MedWatch Safety Information and Adverse Event Reporting Program. FDA is interested in receiving information on the type, manufacturer and NDC numbers of the prefilled syringes and type and manufacturer of needleless IV access devices. FDA is especially interested in any description of the nature of the syringe failure, any adverse patient outcomes, and any mitigation strategies that have been identified or implemented by users of these products.
- Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Read the MedWatch safety alert, including a link to the Drug Safety Communication, at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm234219.htm
Tell us how we are doing:
http://survey.foreseeresults.com/survey/display?cid=d509U9xg0gZVxkMRcoMsQg==&sid=link&cpp[date]=05_06_2011_1524&cpp[type]=S
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Follow MedWatch on Twitter
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@govdelivery.com.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420
No comments:
Post a Comment